A federal court today soundly rejected the Department of Health and Human Service’s interpretation of the 340B statute’s orphan drug exclusion as it relates to providers added to the program in the Affordable Care Act in 2010. The ruling means that rural and cancer hospitals will no longer be able to get 340B pricing on any orphan drug.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)